Woodcock’s Message To OTC Industry: Innovation, Innovation, Innovation
This article was originally published in The Tan Sheet
Executive Summary
Across the board innovation ranging from manufacturing to Rx switch programs is necessary for the OTC industry to spur growth in the future, according to FDA Acting Deputy Commissioner for Operations Janet Woodcock, MD
You may also be interested in...
Senate Hearings Probe FDA Authority On Drug Label Changes, Safety Trials
Giving FDA the authority to require changes to drug labeling could help the agency get drug safety information to the public more quickly, FDA Office of New Drugs Deputy Director Sandra Kweder told the Senate Health Committee March 1
FDA OTC Head Ganley Talks Third Class, Plan B And Drug Switches
This spring, FDA's Division of OTC Drug Products will be elevated to full office status within the Center for Drug Evaluation & Research. OTC Division Director Charles Ganley, MD, sat down with "The Tan Sheet" on Dec. 17 to discuss the ramifications of the organizational change, as well as hot-button issues such as the current Rx-to-OTC switch environment, possible monograph system improvements and advisory committee reviews.